Celladon Corporation Announces Option Agreement With Servier

Published: Feb 24, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that Celladon and Servier have entered into an option agreement for a potential worldwide ex-U.S. research collaboration and license agreement for the discovery and development of novel SERCA2b modulators for the treatment of type 2 diabetes and other metabolic diseases. The collaboration would leverage Celladon's novel compounds, proprietary assays, and screening technology for isolation of small molecule modulators of SERCA enzymes.

Help employers find you! Check out all the jobs and post your resume.

Back to news